Candel Therapeutics, Inc. (CADL) Revenue History
Annual and quarterly revenue from 2019 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
CADL Revenue Growth
CADL Revenue Analysis (2019–2025)
As of May 8, 2026, Candel Therapeutics, Inc. (CADL) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q4 2025) recorded $0 in revenue.
Looking at the longer-term picture, CADL's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $125,000 in 2022.
When compared to Healthcare sector peers including IMCR (+15.6% YoY), IOVA (+34.3% YoY), and FATE (-51.2% YoY). Compare CADL vs IMCR →
CADL Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CADLCurrent | $0 | - | - | - | |
 IMCR | $298M | +15.6% | +58.1% | -11.3% | |
 IOVA | $264M | +34.3% | - | -153.1% | |
 FATE | $7M | -51.2% | -26.7% | -2222.4% | |
 NKTR | $55M | -43.9% | -18.4% | -236.8% |
CADL Historical Revenue Data (2019–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $0 | - | $-48,266,000 | - |
| 2024 | $0 | - | $-990,000 | - | $-33,371,000 | - |
| 2023 | $0 | -100.0% | $-23,980,000 | - | $-38,391,000 | - |
| 2022 | $125K | +0.0% | $125K | 100.0% | $-34,722,000 | -27777.6% |
| 2021 | $125K | +0.0% | $-14,469,000 | -11575.2% | $-25,726,000 | -20580.8% |
| 2020 | $125K | +0.0% | $125K | 100.0% | $-13,810,000 | -11048.0% |
| 2019 | $125K | - | $-6,482,000 | -5185.6% | $-9,037,000 | -7229.6% |
See CADL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CADL Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CADL vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCADL — Frequently Asked Questions
Quick answers to the most common questions about buying CADL stock.
Is CADL's revenue growth accelerating or slowing?
CADL TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is CADL's long-term revenue growth rate?
Candel Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is CADL's revenue distributed by segment?
CADL reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2019-2025 are available for download. Segment mix reveals concentration and diversification trends.